✨ Free AI Report
Ardelyx, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ardelyx, Inc.
Company Research

Ardelyx, Inc.: Business Overview, Financials & Competitive Analysis

Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines that meet significant unmet medical needs. Its flagship therapies IBSRELA treat irritable bowel sy...

Analyst-debate audio for Ardelyx, Inc.

AskCyborg analysts argue the bull and bear cases for Ardelyx, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Strong commercial execution with accelerating revenue growth and clear path to $1B+ annual revenue by 2029 offsetting near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals (GI Therapeutics & Nephrology)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Ardelyx, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Ardelyx, Inc. Overview

Pro stress-test →

Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines that meet significant unmet medical needs. Its flagship therapies IBSRELA treat irritable bowel syndrome with constipation, while XPHOZAH helps dialysis patients manage chronic kidney disease. The company achieved exceptional commercial momentum in 2025 with strong revenue growth.

Strategic Profile

Pro stress-test →

Ardelyx has developed a platform enabling discovery of new biological mechanisms to develop potent and efficacious therapies that minimize side effects and drug-drug interactions. The company expects IBSRELA to achieve $1 billion in annual revenue in 2029, with further growth thereafter. It partners with pharmaceutical entities in Canada, China, and Japan for international expansion.

Competitive Landscape

Pro stress-test →

Ardelyx operates in the gastrointestinal and chronic kidney disease therapeutics markets. Competitors include established players with hyperphosphatemia and IBS-C treatments, but Ardelyx's first-in-class NHE3 inhibitor mechanism and strong commercial execution provide differentiation. The company faces competition from Shire/Takeda (constipation agents) and other phosphate binder manufacturers.

Industry Context

Ardelyx, Inc. operates in Biopharmaceuticals (GI Therapeutics & Nephrology).

Key facts

Headquarters: Waltham, US · Revenue: $407.3M · Market cap: $1.71B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Ardelyx, Inc..

  • IBSRELA delivered significant revenue growth of 73% over 2024, and the company successfully protected patient access to XPHOZAH.
  • Ardelyx highlighted new patents extending protection to 2042 and ongoing late-stage development efforts reinforcing longer-term product and revenue outlook.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026: Announced multi-year partnership with Ladies Professional Golf Association (LPGA)
  • Feb 2026: Reported full-year 2025 revenue of $407.32 million with 2026 guidance of $410-430 million for IBSRELA and $110-120 million for XPHOZAH
  • +1 moreTrack every material event for Ardelyx, Inc. as it happens. Explore monitoring →
Get alerted when Ardelyx, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LinaclotideGI therapy for IBS-C and CIC→Phosphate Binder TherapiesStandard management for hyperphosphatemia in CKD→Emerging GI TherapeuticsCompetitive landscape in constipation management→

Compare Ardelyx, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ardelyx, Inc. operates in Biopharmaceuticals (GI Therapeutics & Nephrology). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals (GI Therapeutics & Nephrology) research →
NEW · MCP server

Ask your AI assistant about Ardelyx, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ardelyx, Inc. and its top competitor on Cyborg Score”
“What did Ardelyx, Inc. do this quarter?”
“Is Ardelyx, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Ardelyx, Inc. do?+
Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines that meet significant unmet medical needs. Its flagship therapies IBSRELA treat irritable bowel sy...
What is Ardelyx, Inc.'s Cyborg Score?+
Ardelyx, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ardelyx, Inc.'s main competitors?+
Named competitors include Linaclotide, Phosphate Binder Therapies, Emerging GI Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Ardelyx, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ardelyx, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ardelyx, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.